---
title: CDMO Daily News — October 16, 2026
slug: daily-news-2026-10-16-cdmo
site: cdmo
post_kind: news
byline: BioBM
description: October 16 CDMO daily: Genezen to Manufacture AAV Gene Therapy for SSADH Deficiency; Lonza Expands Accelerated DNA-to-IND Platform to Bispecific Antibodies…
canonical_url: https://www.cdmo.directory/posts/daily-news-2026-10-16-cdmo
published_at: 2026-10-16T00:00:14.980Z
last_updated: 2026-10-16T00:02:35.857Z
---

### [Genezen](/companies/genezen) to Manufacture AAV Gene Therapy for SSADH Deficiency
- [Genezen](/companies/genezen) will produce preclinical and cGMP clinical material for Galibra Neuroscience's GAL005, an AAV gene therapy for rare neurological disorder SSADH deficiency.
- Manufacturing will occur at Genezen's Indianapolis facility, supporting IND-enabling studies and a planned Phase 1 trial using CapX capsid technology.

**Operational Impact**

[Genezen](/companies/genezen)'s Indianapolis AAV manufacturing capacity is now committed to Galibra's Phase 1 program, demonstrating the CDMO's ability to support rare-disease gene-therapy development from preclinical through early clinical stages.

*Source: [PharmaSource RSS](https://pharmasource.global/content/news/cdmo-news/genezen-partners-with-galibra-neuroscience-on-ssadh-deficiency-gene-therapy)*

---

### [Lonza](/companies/lonza) Expands Accelerated DNA-to-IND Platform to Bispecific Antibodies and Fc-Fusion Proteins
- [Lonza](/companies/lonza) extended its DNA-to-IND pathway to non-monoclonal antibody biologics, including bispecific antibodies, Fc-fusion proteins, and high-concentration formulations.
- The integrated program combines cell line, formulation, analytical, and manufacturing development to deliver toxicology drug substance in three months and IND readiness in six months.

**Operational Impact**

[Lonza](/companies/lonza)'s expanded DNA-to-IND capability for bispecific antibodies and Fc-fusion proteins reduces preclinical-to-IND timelines to six months, enabling CDMO buyers developing complex biologics to compress development risk and accelerate clinical entry.

*Source: [PharmaSource RSS](https://pharmasource.global/content/news/cdmo-news/lonza-expands-dna-to-ind-offering-to-bispecific-antibodies-and-other-biologics)*

---

### Piramal Embeds Patient Centricity as Operational Decision Rule Across 15 Global Sites
- [Piramal Pharma Solutions](/companies/piramalpharmasolutions) has formalized patient centricity as a company-wide operating philosophy, not marketing language, with Patient Awareness Councils at all 15 sites staffed by non-senior volunteers.
- The model uses patient impact as the primary decision filter—overriding revenue conflicts when necessary—and includes mandatory training, annual excellence awards, and CEO-level council engagement.
- Practical application includes holding shipments to resolve invoice disputes and mobilizing pandemic staffing to ensure oncology product delivery, embedding patient outcomes into operational efficiency metrics.

**Operational Impact**

Piramal's formalized patient-centricity framework—including site-level councils, shipment-hold authority for patient-impacting issues, and CEO engagement—signals a competitive differentiation in operational governance that may influence how biotech sponsors evaluate CDMO risk and supply-chain reliability.

*Source: [PharmaSource RSS](https://pharmasource.global/content/podcast/how-piramal-built-patient-centricity-into-15-global-cdmo-sites)*

## References

1. [PharmaSource RSS — Genezen to Manufacture AAV Gene Therapy for SSADH Deficiency](https://pharmasource.global/content/news/cdmo-news/genezen-partners-with-galibra-neuroscience-on-ssadh-deficiency-gene-therapy)
2. [PharmaSource RSS — Lonza Expands Accelerated DNA-to-IND Platform to Bispecific Antibodies and Fc-Fusion Proteins](https://pharmasource.global/content/news/cdmo-news/lonza-expands-dna-to-ind-offering-to-bispecific-antibodies-and-other-biologics)
3. [PharmaSource RSS — Piramal Embeds Patient Centricity as Operational Decision Rule Across 15 Global Sites](https://pharmasource.global/content/podcast/how-piramal-built-patient-centricity-into-15-global-cdmo-sites)

Source: https://www.cdmo.directory/posts/daily-news-2026-10-16-cdmo